117 HRES 1284 RH: Of inquiry directing the Secretary of Health and Human Services to provide certain documentation to the House of Representatives relating to the negotiation of prices for prescription drugs under the Medicare prescription drug program. U.S. House of Representatives 2022-09-30 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IVHouse Calendar No. 140117th CONGRESS2d SessionH. RES. 1284[Report No. 117–534]IN THE HOUSE OF REPRESENTATIVESJuly 26, 2022Mrs. Rodgers of Washington submitted the following resolution; which was referred to the Committee on Energy and CommerceSeptember 30, 2022Reported adversely from the Committee on Energy and Commerce, referred to the House Calendar, and ordered to be printedRESOLUTIONOf inquiry directing the Secretary of Health and Human Services to provide certain documentation to the House of Representatives relating to the negotiation of prices for prescription drugs under the Medicare prescription drug program.

That the Secretary of Health and Human Services (referred to herein as the Secretary) is directed to furnish to the House of Representatives, not later than 14 days after adoption of this resolution, copies of any document, record, audio recording, memorandum, call log, correspondence (electronic or otherwise), or other communication in the Secretary’s possession, or any portion of any document, record, audio recording, memorandum, call log, correspondence (electronic or otherwise), or other communication in the Secretary’s possession, that refers or relates to any of the following:(1)Communications by staff of the White House with any group or expert that is not staff of the White House regarding the implications of imposing a 95 percent excise tax on drug manufacturers that fail to comply with price setting negotiations with the Secretary under the Medicare prescription drug program under part D of title XVIII of the Social Security Act and the potential loss of the development of future drugs and cures.(2)Internal communications among staff of the White House regarding the implications described in paragraph (1) and the potential loss of development described in such paragraph.(3)Communications by staff of the White House with any group or expert that is not staff of the White House regarding the implications of establishing inflation penalties under the Medicare prescription drug program under such part D on launch prices for future prescription drugs.(4)Internal communications among staff of the White House regarding the implications described in paragraph (3).

September 30, 2022Reported adversely from the Committee on Energy and Commerce, referred to the House Calendar, and ordered to be printed